Virtuality Extends Vitae's Reach and Resources
Today's pharmaceutical industry is more dependent on collaborations and cooperative efforts than ever before.
No matter the size of the organization, no company can do everything on its own. At Vitae Pharmaceuticals, we receognize the value of working collaboratively with a broad network of functional experts. By focusing intensely and passionately on our own core competence of structure-based drug discovery and early clinical development, and partnering with other experts to extend and enhance our efforts, we are able to produce tremendous value growth in a fast and highly capital efficient manner.
In January 2004, Vitae Pharmaceuticals announced a collaboration with Intel focused on the development and application of advanced machine learning technology incorporated within our rational drug design computational platform. In addition, Intel chose to make a strategic investment in Vitae Pharmaceuticals. The companies already have made a dramatic impact on computational approaches to drug design by drawing upon both companies' experience in the broad application of machine learning technology.
WuXi PharmaTech, China
Vitae Pharmaceuticals has established a successful partnership with WuXi PharmaTech, integrating WuXi PharmaTech’s highly cost-effective synthetic chemistry with Vitae Pharmaceuticals’ novel structure-based drug discovery expertise and medicinal chemistry know-how. By working in this manner, Vitae Pharmaceuticals can discover, optimize and scale up attractive compounds in a fast and highly capital efficient process.
Virtual Network of Functional Experts
Vitae Pharmaceuticals has formed an extensive virtual network of industry leading outside experts - in functional / technical areas such as CMC, and in therapeutic areas related to our programs – to deliver an unprecedented breadth and depth of expert capability that further enhances innovation, speed and capital efficiency.
Read about our Partnerships for more information.